Oncology pathway explorer
Cancer stemness
Scientific explanation
Stem-like programmes (Wnt, Notch, Hedgehog, ALDH, CD44) can support self-renewal, quiescence and therapy tolerance in a minority population.
Cancers where relevant
Compounds that intersect this pathway
Tetracycline antibiotic that can inhibit matrix metalloproteinases and, at experimental exposures, protein synthesis. Oncology uses remain investigational.
Evidence in mapped cancers: In Vitro · In Vivo · Mechanistically Plausible
Statins (HMG-CoA reductase inhibitors)
Inhibit HMG-CoA reductase, depleting mevalonate-pathway isoprenoids needed for RAS/RHO prenylation and some sterol-dependent growth programmes. Observational oncology signals are mixed and not a licence to treat cancer with statins.
Disulfiram
ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.
Evidence in mapped cancers: In Vitro · In Vivo · Early Clinical
Convergence partners
Other pathways that co-occur with Cancer stemness on mapped adjunct records: NF-κB, Oxidative stress, Invasion, Mitochondrial oxidative phosphorylation.
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.